Contraceptive Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Condoms, Diaphragms, Cervical Caps, Sponges, Vaginal Rings, Intra Uterine Devices (IUDs), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), By End User (Male, and Female), By Region 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 11.54 Billion
CAGR (2026-2031)	6.17%
Fastest Growing Segment	Diaphragms
Largest Market	North America
Market Size (2031)	USD 16.53 Billion

Market Overview

The Global Contraceptive Devices Market will grow from USD 11.54 Billion in 2025 to USD 16.53 Billion by 2031 at a 6.17% CAGR. Contraceptive devices encompass a spectrum of medical implants, physical barriers, and intrauterine systems designed to prevent pregnancy by interfering with the reproductive process. The market is primarily driven by comprehensive government initiatives that subsidize reproductive health services and a growing global prevalence of sexually transmitted infections, which necessitate effective protection mechanisms. These structural drivers establish a baseline of consistent demand, distinct from temporary shifts in consumer preferences or product designs.

According to Family Planning 2030, in 2024, 380 million women and girls in low and lower-middle-income countries were utilizing modern contraception. Despite this substantial user base, the market encounters a significant impediment due to the high costs associated with long-acting reversible methods and limited healthcare infrastructure in developing regions. These financial and logistical barriers restrict wider adoption and hamper the efficient distribution of essential devices to underserved demographics.

Key Market Drivers

The rising prevalence of sexually transmitted infections (STIs) acts as a critical catalyst for the Global Contraceptive Devices Market, necessitating the adoption of barrier methods that offer dual protection against both unintended conception and disease transmission. This surge in infection rates compels public health bodies to aggressively promote condom usage and other physical barriers, thereby sustaining high-volume sales distinct from hormonal implants or intrauterine systems. The urgency of this driver is underscored by recent epidemiological data indicating a failure to curb specific transmission rates globally. According to the World Health Organization, May 2024, in the 'Implementing the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022–2030' report, new syphilis cases among adults aged 15–49 increased by over one million to reach 8 million in 2022, highlighting the immediate requirement for effective barrier interventions.

Supportive government initiatives and family planning programs are simultaneously fundamentally expanding market reach by subsidizing costs and enhancing supply chains in underserved regions. These financial commitments are essential for procuring large volumes of long-acting reversible contraceptives (LARCs) and distribution logistics that private markets often fail to address adequately. According to PAI, April 2024, in the 'Dearly Belated: Congress Finally Completes FY 2024 Appropriations' article, the United States Congress appropriated $607.5 million for international family planning and reproductive health programs for the fiscal year 2024. Furthermore, international organizations play a pivotal role in this ecosystem; according to the United Nations Population Fund, in 2024, their procurement efforts provided 75.2 million couple years of protection through various contraceptive supplies, demonstrating the scale of institutional support driving market volume.

Download Free Sample Report

Key Market Challenges

The high costs associated with long-acting reversible contraceptives (LARCs) and the limited healthcare infrastructure in developing regions constitute a severe restraint on the global contraceptive devices market. Unlike short-term methods, implants and intrauterine systems require significant upfront expenditure and trained medical personnel for insertion, creating a heavy dependency on external funding and robust clinical networks. When supply chains fracture or donor allocations stagnate, these higher-value devices become inaccessible to the populations that need them most. This financial and logistical disconnect prevents the conversion of potential demand into actual market adoption, effectively capping market volume and revenue potential in high-demand regions.

This restriction is quantified by recent data highlighting the magnitude of the gap between demand and supply capabilities. According to the United Nations Population Fund, in 2024, approximately 257 million women in developing regions had an unmet need for modern contraception, a deficit largely attributed to funding shortages and supply chain barriers. This substantial level of unmet demand indicates that despite high awareness, the market is physically and financially unable to reach a vast segment of potential consumers, thereby slowing the overall growth trajectory of the sector.

Key Market Trends

The emergence of reversible male contraceptive technologies is fundamentally altering the sector by introducing viable alternatives to female-centric methods. This trend centers on the development of non-hormonal, vas-occlusive hydrogels that provide long-term efficacy comparable to vasectomies while ensuring reversibility, thereby addressing the significant unmet demand for shared reproductive responsibility. These innovations are progressing rapidly through clinical validation, proving that reliable male-focused devices can effectively disrupt the traditional market reliance on condoms and permanent sterilization. According to MedCity News, January 2024, in the 'Trial Data Looks Promising for 'IUD For Men'' article, clinical trial data for Contraline’s ADAM hydrogel demonstrated that participants achieved a 99.6-100% reduction in motile sperm within 30 days of implantation, confirming the potential for high-efficacy non-hormonal alternatives.

Simultaneously, the rise of direct-to-consumer and online retail channels is reshaping patient access by allowing consumers to bypass traditional clinical gatekeepers. This shift is characterized by the integration of telehealth platforms and agile e-commerce logistics, which enable the discreet and rapid procurement of contraceptives in response to immediate consumer needs or sociopolitical triggers. Unlike government-subsidized programs that depend on slower public infrastructure, private digital health entities leverage flexible distribution networks to capture real-time fluctuations in demand. According to CBS News, November 2024, in the 'Sales of emergency contraceptives surge post-election, companies say' article, online retailer Winx Health reported a 966% spike in sales of their morning-after pill in the 60 hours following the United States election, highlighting the responsiveness of digital channels to acute market dynamics.

Segmental Insights

The Diaphragms segment is currently identified as the fastest-growing category within the Global Contraceptive Devices Market. This rapid expansion is primarily driven by a significant shift in consumer preference toward non-hormonal, reversible contraception, as users increasingly seek to avoid the side effects associated with hormonal alternatives. Additionally, the market has benefited from design advancements, such as the introduction of single-size silicone devices, which eliminate the traditional requirement for clinical fitting. Regulatory clearances by the US FDA for these modern, contoured designs have further enhanced accessibility and user convenience, fueling widespread adoption.

Regional Insights

North America maintains a leading position in the global contraceptive devices market, driven by widespread public awareness regarding family planning and reproductive health. The region benefits from substantial government initiatives intended to curb unintended pregnancies and sexually transmitted infections. Market expansion is further supported by favorable healthcare reimbursement policies and the presence of major industry players. Additionally, the U.S. Food and Drug Administration (FDA) plays a critical role in maintaining safety standards and facilitating product approvals, ensuring consistent access to effective contraceptive solutions across the region.

Recent Developments

• In December 2025, Bayer commenced the Phase III SUNFLOWER clinical study to evaluate the efficacy and safety of its levonorgestrel-releasing intrauterine system (Mirena) for a new indication. The study aims to assess the device as a treatment for nonatypical endometrial hyperplasia, a condition characterized by abnormal thickening of the uterine lining. This research initiative seeks to expand the therapeutic application of the well-established contraceptive device, potentially offering a non-surgical management option for affected patients. The company emphasized that this development underscores its commitment to advancing women's health through rigorous clinical investigation and innovation.
• In August 2025, Femasys Inc. expanded the regulatory reach of its permanent birth control solution, FemBloc, by securing approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. This authorization followed the product's earlier receipt of the CE Mark in Europe, positioning it as a non-surgical, in-office alternative to surgical sterilization. FemBloc functions by delivering a proprietary biopolymer into the fallopian tubes to create a permanent barrier. The company stated that this regulatory achievement was a crucial step in its strategy to commercialize the device globally and provide women with a safer, cost-effective option for permanent contraception.
• In July 2025, Daré Bioscience announced positive interim results from its pivotal Phase 3 clinical study of Ovaprene, an investigational hormone-free monthly intravaginal contraceptive. The data indicated that the device was safe and well-tolerated, with pregnancy rates consistent with expectations derived from earlier pre-pivotal testing. Ovaprene creates a barrier to sperm entry and releases a locally acting spermiostatic agent, offering a potential new category of monthly protection. The company’s President and CEO noted that these findings reinforced the product's potential to serve as a meaningful alternative to traditional hormonal methods.
• In February 2025, Sebela Pharmaceuticals achieved a significant milestone in the contraceptive landscape with the U.S. Food and Drug Administration (FDA) approval of a new hormone-free intrauterine device (IUD). This product, known as MIUDELLA, represents the first approval of a novel copper IUD in the United States in more than four decades. Designed to prevent pregnancy for up to three years, the device utilizes a flexible nitinol frame and a lower dose of copper compared to existing options. The Head of Research and Development at Sebela Women’s Health highlighted that the approval addresses the demand for diverse non-hormonal birth control choices.

Key Market Players

• Cooper Surgical, Inc.
• Pfizer, Inc
• Merck & Co Inc
• AbbVie, Inc
• Teva Pharmaceutical Industries Limited
• Ansell Ltd
• Bayer AG
• Mayer Laboratories Inc
• Church & Dwight Co Inc
• Reckitt Benckiser Group plc

By Product Type	By Distribution Channel	By End User	By Region
Condoms Diaphragms Cervical Caps Sponges Vaginal Rings Intra Uterine Devices (IUDs) and Others	Hospital Pharmacies Retail Pharmacies Online Pharmacies and Others	Male and Female	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Contraceptive Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Contraceptive Devices Market, By Product Type:

• Condoms
• Diaphragms
• Cervical Caps
• Sponges
• Vaginal Rings
• Intra Uterine Devices (IUDs)
• and Others

• Contraceptive Devices Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• and Others

• Contraceptive Devices Market, By End User:

• Male
• and Female

• Contraceptive Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE